ReviewMicrobial cell (Graz, Austria)2016
Genital Herpes: Insights into Sexually Transmitted Infectious Disease.
Review in Microbial cell (Graz, Austria), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Seroprevalence of herpes simplex virus types 1 and 2 in Nigeria: a systematic review and meta-analyses.Pathogens and global health · 2019Pooled it
- Trial
- Topical administration of in situ gelling formulation containing myricetin-polycarboxylate nanoparticles inhibits murine genital herpes infection.International journal of pharmaceutics · 2026Article
- The prevalence of nine human herpesviruses in urogenital samples from young women in Finland.BMC infectious diseases · 2025Article
- Bidirectional transfer of pritelivir across term human placenta and its effect on placental functions.The Journal of pharmacology and experimental therapeutics · 2025Article
- MicroRNAs as regulators of NLRP3 inflammasome activation in herpes simplex virus type 2 infection.Frontiers in cellular and infection microbiology · 2025Article
- Article
- HSV-2 Manipulates Autophagy through Interferon Pathway: A Strategy for Viral Survival.Viruses · 2024Article
- Development and validation of HPLC-ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium.Biomedical chromatography : BMC · 2024Article
- Does genital herpes symptom history predict herpes simplex virus type 2 antibody positivity?International journal of STD & AIDS · 2024Article
- The Interplay of Genital Herpes with Cellular Processes: A Pathogenesis and Therapeutic Perspective.Viruses · 2023Review
- Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications.Cancers · 2023Review
- A Position Statement on Mpox as a Sexually Transmitted Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- LAMP3/CD63 Expression in Early and Late Endosomes in Human Vaginal Epithelial Cells Is Associated with Enhancement of HSV-2 Infection.Journal of virology · 2022Article
- Antiviral activity of triptolide on herpes simplex virus in vitro.Immunity, inflammation and disease · 2022Article
- Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants.Journal of nanobiotechnology · 2022Article
- BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2.Pharmaceutics · 2021Article
- Vaginal delivery of vaccines.Advanced drug delivery reviews · 2021Review
- Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection.Antiviral research · 2021Article
- Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Etiology, transmission and protection: Herpes simplex virus-2 (HSV-2) is a leading cause of sexually transmitted infections with recurring manifestations throughout the lifetime of infected hosts. Currently no effective vaccines or prophylactics exist that provide complete protection or immunity from the virus, which is endemic throughout the world. Pathology/Symptomatology: Primary and recurrent infections result in lesions and inflammation around the genital area and the latter accounts for majority of genital herpes instances. Immunocompromised patients including neonates are susceptible to additional systemic infections including debilitating consequences of nervous system inflammation. Epidemiology, incidence and prevalence: More than 500 million people are infected worldwide and most reported cases involve the age groups between 16-40 years, which coincides with an increase in sexual activity among this age group. While these numbers are an estimate, the actual numbers may be underestimated as many people are asymptomatic or do not report the symptoms. Treatment and curability: Currently prescribed medications, mostly nucleoside analogs, only reduce the symptoms caused by an active infection, but do not eliminate the virus or reduce latency. Therefore, no cure exists against genital herpes and infected patients suffer from periodic recurrences of disease symptoms for their entire lives. Molecular mechanisms of infection: The last few decades have generated many new advances in our understanding of the mechanisms that drive HSV infection. The viral entry receptors such as nectin-1 and HVEM have been identified, cytoskeletal signaling and membrane structures such as filopodia have been directly implicated in viral entry, host motor proteins and their viral ligands have been shown to facilitate capsid transport and many host and HSV proteins have been identified that help with viral replication and pathogenesis. New understanding has emerged on the role of autophagy and other innate immune mechanisms that are subverted to enhance HSV pathogenesis. This review summarizes our current understanding of HSV-2 and associated diseases and available or upcoming new treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.